---
title: 'Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP
  in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre,
  parallel, open-label, phase 3 trial'
date: '2024-07-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38971175/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240707183234&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Intensified systemic chemotherapy has the highest primary
  cure rate for advanced-stage, classical Hodgkin lymphoma but this comes with a cost
  of severe and potentially life long, persisting toxicities. With the new regimen
  of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and
  dexamethasone (BrECADD), we aimed to improve the risk-to-benefit ratio of treatment
  of advanced-stage, classical Hodgkin lymphoma guided by PET after two ...'
disable_comments: true
---
BACKGROUND: Intensified systemic chemotherapy has the highest primary cure rate for advanced-stage, classical Hodgkin lymphoma but this comes with a cost of severe and potentially life long, persisting toxicities. With the new regimen of brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD), we aimed to improve the risk-to-benefit ratio of treatment of advanced-stage, classical Hodgkin lymphoma guided by PET after two ...